Loading market dashboard
Pelthos Therapeutics Inc.
PTHSHealthcareAMEXUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that CEO Scott Plesha will present at 11:05 am ET and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. Investors interested in arranging one-on-one meetings should contact their Jefferies representative.
Pelthos Therapeutics NYSEAMERICAN: PTHS reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment's third full quarter since launch, executives said on the company's 2026 first-quarter earnings call.
Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $3.09 per share versus the Zacks Consensus Estimate of a loss of $4. This compares to a loss of $3.2 per share a year ago.
ZELSUVMI ® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique prescribers for the first quarter of 2026, with a 25% quarter over quarter increase in units dispensed Management will host a conference call today, May 14, 2026, at 8:30 a.m. ET DURHAM, N.C.
DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report first quarter 2026 financial results on Thursday, May 14, 2026.
First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease
Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $3.95. This compares to a loss of $3.2 per share a year ago.
ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025.
DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that CEO Scott Plesha will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026 at 3:00 p.m. Pacific Time.
